Peglylated granulocyte colony-stimulating factor consists of the active ingredient Peglylated granulocyte colony-stimulating factor. This is synthesized from the bacteria E.coli. It belongs to a category of proteins called cytokines and is similar to the natural protein produced by the body. It is a leucocyte growth factor indicated to reduce infections in patients receiving anti-cancer drugs with bone marrow suppressive properties. Peglylated granulocyte colony-stimulating factor was approved by the US Food and Drug Administration (FDA) on February 20, 2002, for reducing the incidence of infection, as manifested by febrile neutropenia (decreased white blood cell count).

Pegylated granulocyte colony-stimulating factor is used for patients with chemotherapy-induced neutropenia, chemotherapy-induced fever, and chemotherapy-induced infections.

Peglylated granulocyte colony-stimulating factor is administered as an injection under the skin. The injection should be given in the abdomen (at least 2 inches away from the belly button), the front of the thighs, or the upper arm. It is usually administered once per chemotherapy cycle. The medication should be administered at least 24 hours after the last dose of chemotherapy to allow for proper bone marrow recovery.

The most common side effects of Peglylated granulocyte colony-stimulating factors include bone pain, headache, fatigue, and musculoskeletal pain. Less common side effects include allergic reactions, including anaphylaxis, spleen rupture, acute respiratory distress syndrome (ARDS), and glomerulonephritis.

Rare cases of splenic rupture have been reported in patients receiving Peglylated granulocyte colony-stimulating factor. In rare cases, this medication can cause ARDS, a serious lung condition that can cause shortness of breath, coughing, and fatigue. Patients should notify their healthcare provider immediately if they experience any symptoms of ARDS. It can cause allergic reactions in some patients, which can be severe or life-threatening. This medicine should be used cautiously in patients with sickle cell disease, as it can increase the risk of a sickle cell crisis. There have been reports of secondary malignancies, such as leukemia and myelodysplastic syndrome, in patients receiving this medicine.

You should be monitored for signs and symptoms of splenic ruptures, such as left upper abdominal pain or shoulder pain while receiving Peglylated granulocyte colony-stimulating factor. You should notify your healthcare provider immediately if these symptoms occur. Patients should tell the healthcare provider immediately if they experience any symptoms of ARDS. you require close monitoring for signs of an allergic reaction, such as rash, itching, or swelling. Patients with sickle cell disease also required close monitoring during treatment.

Remember always to follow your healthcare provider's instructions when taking Peglylated granulocyte colony-stimulating factor or any medication. Patients should be monitored for signs of an allergic reaction, such as rash, itching, or swelling, and should seek immediate medical attention if these symptoms occur. If you have any questions or concerns, do not hesitate to discuss them with your healthcare provider. Be aware of potential side effects and notify your healthcare provider if you experience any unusual symptoms. It should be used with caution in patients with severe renal impairment. Pregnant and breastfeeding women should discuss potential risk and benefit with a healthcare provider before taking this medication. Always maintain a healthy and balanced diet to support your overall health and well-being.

1. Amgen Inc., [Revised on Feb 2021] [Accessed on 2 May 2023], https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.pdf
2. Accord Healthcare Limited, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 2nd May 2023], https://www.medicines.org.uk/emc/files/pil.9531.pdf
3. James L. Zehnder, Agents Used in Cytopenias; Hematopoietic Growth Factors, Lange’s Basic & Clinical Pharmacology, 14th Edition, 2018, 591-607
4. Maureen S. Phillips, Peglylated granulocyte colony-stimulating factor, Clinical Journal of Oncology Nursing, 2003, 7(2), 238, https://cjon.ons.org/sites/default/files/5205800724MRU571_first.pdf

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.